January 1, 2014Toxicology ReportsOpen Access

A peripherally restricted P2Y12 receptor antagonist altered rat tumor incidences with no human relevance: Mode of action consistent with dopamine agonism

View Full Paper

Ask AI

Bookmark

Population

Male and female rats

Design

Preclinical

Follow-up

2 years (for carcinogenicity study)

Authors

DBDavid BrottAstraZeneca (United Kingdom)HAHåkan AnderssonVäxjö Kommun JSJane StewartAstraZeneca (United Kingdom)

Discussion

Member takes

Implication

Supports lack of human translation for ticagrelor rat tumors; leaves open prolactin mechanism validation in clinical research.

Structured PICO

Population

Male and female rats (evaluated via 2-year carcinogenicity study, in vitro and in vivo genotoxicity assays, quantitative whole body autoradiography, and in vivo ovariectomized rat assay)

Intervention

Ticagrelor

Outcome

Tumor incidence (uterine, mammary, and pituitary) and mode of actionsafety

Ticagrelor-induced uterine tumors in rats are driven by a dopamine-mediated mechanism that does not translate to human clinical risk.

Cite This Study

Brott et al. (2014) studied this question.

synapsesocial.com/papers/6a77e0c93da069e66cbdd67f https://doi.org/10.1016/j.toxrep.2014.11.010

View Full Paper

Ask AI

Bookmark

A peripherally restricted P2Y12 receptor antagonist altered rat tumor incidences with no human relevance: Mode of action consistent with dopamine agonism

Discussion

Member takes

Implication

Structured PICO

Cite This Study

A peripherally restricted P2Y12 receptor antagonist altered rat tumor incidences with no human relevance: Mode of action consistent with dopamine agonism

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider